MedPath
HSA Approval

HOVA EXPECTORANT

SIN03251P

HOVA EXPECTORANT

HOVA EXPECTORANT

June 12, 1989

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05CA10

combinations

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

HOVID BHD

Active Ingredients

SODIUM CITRATE

57 mg/5 ml

Sodium citrate

DIPHENHYDRAMINE HCl

14 mg/5 ml

Diphenhydramine

AMMONIUM CHLORIDE

135 mg/5 ml

Ammonium chloride

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

HOVA EXPECTORANT - HSA Approval | MedPath